Survodutide clinical trials
Survodutide is named as an intervention in 4 current clinical trials in our USA, India, Canada, Australia, Netherlands and Germany registers. 1 is recruiting patients now. The most common phase is Phase 1. The lead sponsor is Boehringer Ingelheim. The most-studied condition is Obesity. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
How Survodutide works
All drug targets →- Glucagon-like peptide 1 receptor agonist AgonistTarget: GLP1R glucagon like peptide 1 receptor✓ In ChEMBL and the Guide to Pharmacology
- Glucagon receptor agonist AgonistTarget: GCGR glucagon receptor✓ In ChEMBL and the Guide to Pharmacology
- Hepatic fibrosisPhase 3
- OverweightPhase 3
- Cirrhosis of liverPhase 3
- Metabolic dysfunction-associated steatohepatitisPhase 3
- Obesity disorderPhase 3
- Type 2 diabetes mellitusPhase 3
- AlbuminuriaPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL5314776, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 13383, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Survodutide
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Survodutide
4 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
NCT07754461 · Type 2 Diabetes
|
Phase 3 | Recruiting | Boehringer Ingelheim | USA, India, Canada, Australia |
|
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
NCT05202353 · ClinicalTrials.gov ↗ · Obesity
|
Phase 1 | Active, closed | Boehringer Ingelheim | Netherlands |
|
A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity
NCT06745284 · Obesity
|
Phase 1 | Active, closed | Boehringer Ingelheim | USA |
|
A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity
NCT07768813 · ClinicalTrials.gov ↗ · Healthy, Obesity
|
Phase 1 | Active, closed | Boehringer Ingelheim | Germany |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Survodutide in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Survodutide. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Albuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD)
2025-525068-13-00 · CTIS ↗ · Nutritional and Metabolic Diseases
|
Phase 2 | Authorised | Universitair Medisch Centrum Groningen | Germany, Spain, Netherlands |
Conditions studied with Survodutide
3 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Boehringer Ingelheim | 4 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 2 | 1 |
| Clinical trials in India | 1 | 1 |
| Clinical trials in Canada | 1 | 1 |
| Clinical trials in Australia | 1 | 1 |
| Clinical trials in Netherlands | 1 | 0 |
| Clinical trials in Germany | 1 | 0 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Survodutide trials
How many clinical trials are testing Survodutide?
4 current trials in our USA, India, Canada, Australia, Netherlands and Germany registers name Survodutide (also registered as BI 456906) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Survodutide trials recruiting patients?
Yes. 1 of the 4 trials is recruiting: 1 with sites in USA, 1 with sites in India, 1 with sites in Canada and 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Survodutide clinical trials?
The lead sponsor is Boehringer Ingelheim. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Survodutide works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Survodutide works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Survodutide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.